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INTRODUCTION
The Polish Society of Hypertension (PTNT) presents a new 
edition of its guidelines for the management of hypertension.
During 4 years that have passed since publication of 
the previous 2011 guidelines, results of multiple studies 
and metaanalyses evaluating antihypertensive therapy have 
been published. These results have extended the range 
of available information, leading to modification of some 
previous concepts, such as the approach to the treatment 
of resistant and secondary hypertension, including inter-
ventional treatment.
The present document is generally based on the 2011 PTNT 
guidelines and includes some of the changes, which were con-
sidered appropriate by the authors of the present guidelines, 
that were introduced in the most recent European Society 
of Hypertension/European Society of Cardiology (ESH/ESC) 
guidelines published in 2013. 
A novel aspect of the 2015 PTNT guidelines has been 
the addition of an extensive chapter on the management of 
hypertension in children, based on the fact that hypertension 
specialists in training may stem from both internists and pae-
diatricians (available in full version), and an attempt to make 
this guideline edition more practical, taking into considera-
tion some specific Polish conditions and issues regarding the 
diagnosis and drug treatment.
A traffic light (in original version) signalling system-based 
classification has been introduced in the tables summarising 
the basic principles of the management of hypertension in 
special patient populations, with the three colours correspond-
ing in a simplified way to typical recommendation classes 
along with their levels of evidence, but also reflecting expert 
opinion to a greater degree compared to the 2013 ESH/ESC 
guidelines. These colours mean:
 —  light grey (green in original version) — a given man-
agement approach is recommended, generally based 
on clear evidence from research studies, or unequivocal 
expert opinion resulting from everyday clinical practice;
 —  grey (yellow in original version) — a given manage-
ment approach is suggested as appropriate despite lacking 
or equivocal evidence from research studies, based on 
the opinion of the majority of experts reflecting common 
sense and their personal clinical experience;
 —  blue (red in original version) — a given management 
approach is considered harmful, generally based on clear 
evidence from research studies, or not justified due to lack 
of supporting evidence.
1. EPIDEMIOLOGY AND PREVENTION  
OF HYPERTENSION
Hypertension remains the most important risk factor for 
premature mortality worldwide. Blood pressure (BP) values 
show a linear correlation with mortality and the incidence of 
cardiovascular disease (CVD — myocardial infarction [MI], 
stroke, heart failure [HF], peripheral vascular disease) and 
chronic kidney disease (CKD) in all age and ethnic groups in 
both women and men.
Data obtained during the last 20 years indicate an in-
creasing prevalence of hypertension in Poland. The NATPOL 
2011 study showed that over 10 years, the prevalence of 
hypertension in individuals aged 18–79 years increased from 
30% to 32%, or approximately 9 million. In addition, the 
POLSENIOR study indicates that hypertension is present in 
about one million of people above 80 years of age. If these 
trends continue, it has been estimated that the number of sub-
jects with hypertension will have increased by half until 2035.
Development of hypertension may be best prevented 
by interventions targeted at environmental factors. The 
most effective approach to prevent or delay development of 
hypertension (primary prevention) is lifestyle modification, 
in particular prevention of obesity and increasing physical 
activity. Primary prevention may be divided into population 
efforts, directed at the general population, and prevention 
targeted at those at an increased risk of hypertension. The 
latter should focus on the following groups:
 — subjects with a family history of premature CVD (stroke, 
MI, HF) — below 65 years of age in women and 55 years 
of age in men;
 — patients with diabetes or concomitant kidney disease;
 — subjects with two or more conventional cardiovascular 
(CV) risk factors;
 — subjects with high normal BP (≥ 130/85 mm Hg);
 — subjects with white coat hypertension.
About 30% of subjects are unaware of hypertension 
which results from the fact that nearly 40% of people in Poland 
do not know their BP values. Due to this low identification 
of hypertension in Poland, screening BP measurements are 
recommended in all adults at least once a year regardless of 
previous BP values. The proportion of subjects with the diag-
nosis of hypertension who remained untreated decreased 
from 18% to 13%. A positive trend has been also the observed 
increase in the proportion of hypertensive subjects with ad-
equately controlled BP from 12% to 26%. This is related to 
the fact that the proportion of adequate BP control among 
treated subjects increased from 22% to 42%.
2. DIAGNOSIS AND CLASSIFICATION
Hypertension may be diagnosed if average BP values (calcu-
lated based on at least two measurements on at least two 
different visits) are equal to or higher than 140 mm Hg (SBP, 
systolic blood pressure) and/or 90 mm Hg (DBP, diastolic 
blood pressure).
In patients with BP values below 160/100 mm Hg, the 
diagnosis of hypertension should be confirmed by ambula-
tory blood pressure monitoring (ABPM) or, if this method is 
not available, by home BP measurements, using different 
threshold values as shown in Table 1.
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In patients with BP values ≥ 180/≥ 110 mm Hg, the 
diag nosis of hypertension may be made at the first visit after 
excluding the effect of factors leading to acute BP elevation, 
e.g. anxiety, pain, or alcohol intake.
The diagnosis of hypertension may also be made based 
on reliable data from the history or patient medical records 
(BP values or the use of antihypertensive medications).
In the present 2015 PTNT guidelines, we retained the 
previous classification of hypertension based on office BP 
measurements, with three grades of severity and the separate 
subtype of isolated systolic hypertension (ISH). The classifica-
tion also continues to categorise BP values in the normal range 
into optimal, normal, and high normal BP.
Detailed classification of hypertension is shown in Table 2.
Blood pressure values are of major importance when 
stratifying patient risk. The remaining components required 
for this assessment must be obtained by the physician based 
on history, physical examination, and laboratory tests.
3. INVESTIGATIONS
At the time of the diagnosis of hypertension, all patients should 
undergo comprehensive evaluation that includes detailed 
history, physical examination, and selected laboratory tests 
and other investigations as required.
The goals of clinical evaluation include identification of:
 — other concomitant CV risk factors;
 — target organ damage and the presence and severity of oth-
er diseases, including CVD, kidney disease, and diabetes;
 — the cause of elevated BP and indications for investigating 
for possible secondary hypertension.
Table 1. Diagnosis of hypertension based on office and out-of-office blood pressure (BP) measurements
Category Systolic BP [mm Hg] Diastolic BP [mm Hg]
Office BP measurements ≥ 140 and/or ≥ 90
Ambulatory BP measurements
 — daytime (or awake) ≥ 135 and/or ≥ 85
 — nighttime (or sleep) ≥ 120 and/or ≥ 70
 — mean 24-h ≥ 130 and/or ≥ 80
Home BP measurements ≥ 135 and/or ≥ 85
Table 2. Definitions and classification of office blood pressure (BP) levels
Category Systolic BP [mm Hg] Diastolic BP [mm Hg]
Optimal BP < 120 and < 80
Normal BP 120–129 and/or 80–84
High normal BP 130–139 and/or 85–89
Grade 1 hypertension 140–149 and/or 90–99
Grade 2 hypertension 160–179 and/or 100–109
Grade 3 hypertension ≥ 180 and/or ≥ 110
Isolated systolic hypertension ≥ 140 and < 90
3.1. Laboratory investigations
Laboratory investigations include routine tests necessary in 
all patients with hypertension, additional tests performed 
in selected patients, and specialist tests performed during 
more extensive diagnostic work-up in reference centres are 
shown in Table 3.
3.2. Ambulatory blood pressure monitoring
Increasing the number of BP measurements performed 
out-of-office, in conditions that reflect the usual patient en-
vironment, allows more reliable evaluation of actual BP val-
ues. Different diagnostic thresholds for out-of-office measure-
ments compared to office measurements have been included 
in the diagnostic criteria for hypertension. Normal BP by ABPM 
is defined as mean daytime values below 135/85 mm Hg, 
mean nighttime values below 120/70 mm  Hg, and mean 
24-h values below 130/80 mm Hg. Mean BP values obtained 
by ABPM or home blood pressure monitoring (HBPM) better 
reflect the risk of CV events and correlate more strongly with 
the presence of subclinical target organ damage compared 
to office BP values. Out-of-office measurements allow the 
diagnosis of masked hypertension, which is characterised by 
elevated BP values only in ABPM or HBPM, and are necessary 
for modifications of the timing of antihypertensive drug ad-
ministration. Despite clear clinical utility, ABPM also has some 
limitations including high cost, still suboptimal availability, and 
unclear reproducibility of findings (though the latter is higher 
compared to office BP measurements). To obtain reliable 
measurements, validated devices should be used, and care 
should be taken to ensure proper measurement technique.
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The use of ABPM has increased in the recent years, as 
reflected by extended indications for this investigation in 
the 2011 British Society of Hypertension (BSH)/National 
Institute for Clinical Excellence (NICE) guidelines and the 
2013 ESH/ESC guidelines. ABPM allow detection of prognos-
tically adverse phenomena including excessive morning BP 
surge, and non-dipper and extreme-dipper patterns of the 
circadian BP rhythm. Clearly, ABPM should be widely used 
to diagnose hypertension, particularly in patients with grade 
1 hypertension by office BP measurements. Specific indica-
tions for ABPM are listed in Table 4.
3.3. Home blood pressure measurements
Home BP measurements not only reduce the risk of 
a white-coat effect, often observed during office BP measure-
ments, but also show good agreement with daytime ABPM 
measurements. In addition, home BP values correlate with CV 
risk better than office values. Abnormal home BP values are 
defined as the average of several measurements greater 
than or equal to 135 mm Hg and/or 85 mm Hg.
During long-term management, 1–2 measurements per 
week are recommended, with values recorded in a patient 
diary. Daily home measurements should be advised dur-
ing the week prior to a follow-up visit (2 measurements in 
the morning and 2 measurements in the evening, before 
Table 4. Indications for and technique of ambulatory blood 
pressure measurements (ABPM)
Indications for ABPM
Confirmation of the diagnosis of hypertension in patients with 
grade 1 hypertension by office BP measurements and low/moderate 
cardiovascular risk
Suspicion of white-coat hypertension
 — grade 1 hypertension by office BP measurements
 — long-standing hypertension without target organ damage 
and/or with low global cardiovascular risk
 — large BP differences in office measurements (> 20 mm Hg) or 
differences between home and office readings
Suspicion of masked hypertension
 — high normal BP by office measurements
 — normal office BP readings in individuals with subclinical target 
organ damage or high global cardiovascular risk
 — suspicion of nocturnal hypertension and/or abnormal 24-h BP 
pattern
Suspicion of hypotension (dizziness, falls, presyncope, syncope) or 
autonomic system dysfunction
Identification of true resistant or pseudo resistant hypertension
 — suspicion of white-coat effect in treated hypertensives
Hypertension in pregnant women
Hypertension in patients with glaucoma
Technique of ABPM
First, measure BP on both arms with a conventional  
sphygmomanometer according to the general principles 
Depending on BP difference between arms:
≤ 10 mm Hg (SBP) — place the cuff on the non-dominant arm
> 10 mm Hg — place the cuff on the arm with higher BP reading
Choose an appropriately-sized cuff and measure BP using the 
automated device
If the difference between initial BP reading and BP read by the 
automated device is greater than 5 mm Hg, re-adjust the cuff
Set BP measurement intervals (preferred intervals 15–20 min during 
the day and 30 min during the night, maximum acceptable  
intervals 30 min during the day and 60 min during the night)
Switch off BP reading display
Provide the patient with a diary to record activity during the  
monitoring (along with a contact phone number)
A recording is acceptable if it includes at least 70% of the planned 
BP readings during the day and night
BP — blood pressure; SBP — systolic blood pressure
Table 3. Routine, additional, and specialist laboratory investi-




Serum total cholesterol, LDL-C, HDL-C, and triglycerides
Serum potassium, sodium, and uric acid





Carotid and renal artery ultrasound
Quantitative evaluation of proteinuria (if positive reagent strip test); 
urinary sodium and potassium
Fundoscopy
Oral glucose tolerance test
24-h ambulatory blood pressure monitoring
24-h Holter monitoring if arrhythmias
Ankle-brachial index measurement
Pulse wave velocity measurement
Specialist tests
Further search for cerebral, cardiac, renal and vascular damage, 
mandatory in resistant or complicated hypertension
Search for secondary hypertension when suggested by clinical 
evidence or results of previous investigations
GFR — glomerular filtration rate; HDL-C — high-density lipoprotein 
cholesterol; LDL-C — low-density lipoprotein cholesterol
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Table 5. Risk factors, target organ damage, and metabolic, 
cardiovascular, and renal disease used for stratification of  
the global cardiovascular risk (see Fig. 1)
Risk factors
Male sex
Age (men ≥ 55 years, women ≥ 65 years)
Smoking
Dyslipidaemia:
 — total cholesterol > 4.9 mmol/L (190 mg/dL), and/or
 — LDL cholesterol > 3.0 mmol/L (115 mg/dL), and/or
 — HDL cholesterol < 1.0 mmol/L (40 mg/dL) in men,  
< 1.2 mmol/L (46 mg/dL) in women, and/or
 — triglycerides > 1.7 mmol/L (150 mg/dL)
Fasting plasma glucose 5.6–6.9 mmol/L (102–125 mg/dL)
Abnormal glucose tolerance test
Obesity (BMI ≥ 30 kg/m2)
Abdominal obesity (waist circumference:  
men ≥ 102 cm, women ≥ 88 cm — in Caucasians)
Family history of premature CVD (men < 55 years,  
women > 65 years)
Subclinical target organ damage
Pulse pressure (in the elderly) ≥ 60 mm Hg
Electrocardiographic LVH
 — Sokolov–Lyon index > 3.5 mV
 — R in aVL > 1.1 mV
 — Cornell voltage duration product > 244 mV × ms
or echocardiographic LVH
 — LVM index > 115 g/m2 BSA in men, > 95 g/m2 BSA in women
Carotid artery wall thickening (IMT > 0.9 mm) or the presence of 
a atherosclerotic plaque
Carotid artery-femoral artery PWV > 10 m/s
Ankle–brachial index < 0.9
Chronic kidney disease with eGFR 30–60 mL/min/1.73 m2 BSA
Albuminuria 30–300 mg/24 h or urinary albumin-creatinine ratio 
30–300 mg/g (3.4–34 mg/mmol) (preferentially on morning 
spot urine)
Diabetes
Fasting plasma glucose ≥ 7.0 mmol/L (126 mg/dL) on two  
measurements
Random glucose ≥ 11.1 mmol/L (200 mg/dL) if symptoms of  
hyperglycaemia are present, such as polydipsia, polyuria, fatigue
Post-load plasma glucose ≥ 11.1 mmol/L (200 mg/dL)
Overt cardiovascular or renal disease
Cerebrovascular disease: ischaemic stroke, cerebral haemorrhage, TIA
CVD: myocardial infarction, angina, myocardial revascularisation 
with PCI or CABG
Heart failure, including heart failure with preserved EF
Symptomatic lower extremities peripheral arterial disease
Chronic kidney disease with eGFR < 30 mL/min/1.73 m2 BSA, 
proteinuria > 300 mg/24 h
Advanced retinopathy: haemorrhages or exudates, papilledema
BMI — body mass index; BSA — body surface area; CABG — coronary 
artery bypass grafting; CVD — cardiovascular disease; EF — ejection 
fraction; eGFR — estimated glomerular filtration rate; HDL — high-
-density lipoprotein; IMT — intima–media thickness; LDL — low-density 
lipoprotein LVH — left ventricular hypertrophy; LVM — left ventricular 
mass; PCI — percutaneous coronary intervention; PWV — pulse wave 
velocity; TIA — transient ischaemic attack
Æ
Clinical profile Blood pressure [mm Hg]
High normal  
(130–139/85–89)
Grade 1 hypertension 
(140–159/90–99)
Grade 2 hypertension 
(160–179/100–109)
Grade 3 hypertension 
(≥ 180/110)
No risk factors Average* Low Moderate High
1–2 risk factors Low Moderate Moderate High
≥ 3 risk factors Moderate Moderate High High
Target organ damage, 
diabetes, CKD stage 3
High High High Very high
Overt cardiovascular 
disease, CKD stage ≥ 4
Very high Very high Very high Very high
Figure 1. Evaluation of the global cardiovascular (CV) risk in hypertensive patients 
*Denotes CV risk in the healthy population, which is lower than a “low” global cardiovascular risk in respective age groups 
CKD — chronic kidney disease (stage 3: eGFR 30–59 mL/min/1.73 m2; stage ≥ 4: eGFR < 30 mL/min/1.73 m2) 
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medication intake) and are a basis for medication adjust-
ments by a physician.
3.4. Assessment of the global cardiovascular risk
In most patients, other concomitant factors affecting the 
global CV risk may be detected at the time of the diagnosis 
of hypertension. Thus, the management of a hypertensive 
patient should include estimation of CV risk based on the 
severity of hypertension and the presence of other major risk 
factors, subclinical target organ damage, and concomitant 
diabetes, CVD, or CKD. The risk is then categorised as low, 
moderate, high, or very high. Assessment of the global CV 
risk is the basis of therapeutic choices regarding many 
aspects of the management and treatment strategy in 
a hypertensive patient.
Table 5 summarises risk factors, subclinical target organ 
damage, CVD and kidney disease taken into account when 
evaluating the risk of a CV event, and stratification of the global 
risk based on these factors is shown in Figure 1.
When based on the Framingham model, interpretation 
of the level of risk (low, moderate, high, or very high), which 
is higher compared to healthy subjects without risk factors, 
indicates that the 10-year absolute risk of CVD is below 
15%, 15–20%, 20–30%, and above 30%, respectively. Using 
the European Systematic Coronary Risk Evaluation (SCORE) 
model, the 10-year absolute risk of CV death for the above risk 
categories is below 4%, 4%, 5–8%, and above 8%, respectively. 
Use of the SCORE risk chart is recommended in subjects above 
40 years of age free from CVD and diabetes. For younger 
subjects, a relative risk chart is available (see: Eur Heart J, 
2012; 33: 1635–1701).
In patients with an abnormal circadian BP pattern 
(non-dippers, extreme dippers), the global risk is increased 
in relation to the observed BP values.
In patients with masked hypertension, the global risk is 
similar to that in subjects with office hypertension. In contrast, 
the risk in those with white-coat hypertension is lower than 
indicated by office BP measurements.
4. THERAPEUTIC MANAGEMENT
4.1. Overall goals and principles  
of the management
The basic goal of treatment in patients with hypertension 
is to reduce mortality and the global risk of CV and renal 
complications. In particular, drug treatment should reduce 
BP values to target levels established for hypertensives or, 
if it is not feasible, as close to these values as possible. This is 
based on numerous observations that effective BP lowering 
reduces the risk of CV events, particularly stroke and acute 
coronary events, and delays progression of renal disease. At 
the same time, global treatment strategy in the hyperten-
sive patient should include correcting all other modifiable 
CV risk factors.
4.1.1. Initiation of antihypertensive therapy
The decision to initiate antihypertensive therapy should 
be preceded by history taking and physical examination, 
including BP measurements according to the above de-
fined standards. If grade 3 (BP ≥ 180 and/or 110 mm Hg) 
or grade 2 (BP ≥ 160 and/or 100 mm Hg) hypertension is 
found, as confirmed by at least two measurements at one or 
two occasions, respectively, drug treatment should be initi-
ated immediately along with necessary non-pharmacological 
measures, prior to complete evaluation of the risk profile.
If the observed BP values indicate grade 1 hypertension 
(140–159/90–99 mm Hg), non-pharmacological measures 
should be instituted, and the decision to initiate drug therapy 
should be made after comprehensive risk stratification and 
evaluation of the effects of non-drug treatment, and if the 
global CV risk is low or moderate, also following additional 
verification of the diagnosis of hypertension by ABPM. This 
indicates that it is not necessary to start drug treatment in pa-
tients with white-coat hypertension, and only lifestyle changes 
and periodic reevaluation by ABPM should be recommended 
instead, as these individuals are at an increased risk of devel-
oping true hypertension. Despite little evidence of benefits of 
antihypertensive therapy in patients with grade 1 hyperten-
sion, there are arguments in favour of initiating drug treatment 
at some point also in these patients, as summarised in the 
2013 ESH/ESC guidelines: (i) withholding drug therapy leads 
over time to an increase in the global risk which is difficult 
to reverse, (ii) appropriately individualised antihypertensive 
drug therapy is effective and well tolerated long-term, and 
(iii) cheap antihypertensive drugs are available that provide 
a good benefit-to-cost ratio.
If grade 1 hypertension is confirmed in an elderly pa-
tient, the decision to initiate drug treatment should be more 
cautious and is not obligatory due to the fact that evidence 
of benefits of antihypertensive drug therapy in this age 
group come from studies that recruited patients with at least 
grade 2 hypertension. On the other hand, elderly patients 
constituted a significant proportion of patient populations 
in many large-scale clinical trials that showed benefits of 
antihypertensive drug therapy.
The 2013 ESH/ESC guidelines suggested that lifestyle chang-
es only should be instituted in young subjects with grade 1 ISH, 
as there is no evidence of treatment benefits in this age group, 
and their central aortic pressure is often normal. It seems that 
the decision to initiate drug treatment in these patients should 
be individualised based on the evaluation of their global CV 
risk, possibly measurement of central BP, and after mandatory 
verification of the diagnosis of hypertension by ABPM.
Routine antihypertensive drug therapy in patients with 
high normal BP (130–139/85–89 mm Hg) continues to be con-
sidered unnecessary regardless of the presence of metabolic 
syndrome, diabetes, and/or CVD (ischaemic heart disease 
[IHD], previous MI or stroke). In the latter group, antihyper-
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tensive drug may be necessary for other indications (secondary 
prevention of MI, treatment of HF, nephroprotection).
Non-drug treatment involving lifestyle changes is a nec-
essary component of the management of hypertension and 
should be initiated at the first visit in all patients with suspected 
hypertension, including those with high normal BP. Initiating 
drug treatment does not mean that lifestyle changes are no 
longer necessary. At the same time, due to low patient compli-
ance regarding lifestyle changes, institution of non-drug treat-
ment should not delay the decision to initiate antihypertensive 
drug therapy beyond the time limits set for this decision, 
particularly in patients with higher CV risk.
The principles of initiating drug therapy are summarised 
in Figure 2.
4.1.2. Target blood pressure
Target BP is a threshold value below which patient’s BP should 
be kept during optimal antihypertensive therapy. Only once 
target BP values are reached, there is no need for further 
therapy intensification. In the past, recommendations regard-
ing target BP values were often changed with publication 
of the results of large trials comparing benefits of different 
target BP values during treatment. Current analyses indicate 
that optimal reduction of the global CV risk is obtained by 
reducing BP below 140/90 mm Hg in most patients with 
hypertension, including those with concomitant IHD, 
previous MI, or stroke. This major change in the approach 
to setting target BP in patients with high baseline CV risk 
that occurred in 2009 and was maintained in the present 
guidelines, is related, among others, to the existence of a phe-
nomenon of the J curve, i.e. relatively higher CV risk with too 
low on-treatment BP values, which was observed in many 
large-scale clinical trials. In patients at high CV risk, however, 
BP should be reduced more rapidly to the target values.
There are two exceptions from the target BP given above. 
In patients with diabetes, the recommended target BP 
values are below 140/85 mm Hg. This conclusion results 
from multiple analyses showing the nadir of CV risk at these 
BP values in diabetic patients (based on the ACCORD, HOT, 
and INVEST studies). In patients above 80 years of age, more 
cautious SBP reduction to values below 150 mm Hg is rec-
ommended, based directly on the target SBP set in the HYVET 
trial which was the only successful study in this age group.
In patients with ISH, SBP should be reduced below 
140 mm Hg but due to low DBP values, advanced age of 
most patients with this subtype of hypertension, and less 
Clinical profile Blood pressure [mm Hg]
High normal  
(130–139/85–89)
Grade 1 hypertension 
(140–159/90–99)
Grade 2 hypertension 
(160–179/100–109)
Grade 3 hypertension 
(≥ 180/110)
Non-drug therapy and antihypertensive drug therapy
No risk factors No intervention Lifestyle changes: 
confirmation by ABPM 
if BP ≥ 140/90 after 
3 months, then add drugs
Lifestyle changes  
+ drug treatment starting 
from the 2nd visit
Lifestyle changes  
+ drug treatment starting 
from the 1st visit
1–2 risk factors Lifestyle changes
≥ 3 risk factors Lifestyle changes
Lifestyle changes: 
confirmation by ABPM 
if BP ≥ 140/90 after 
3 months, then add drugs
Lifestyle changes  
+ drug treatment starting 
from the 2nd visit
Target organ damage, 
diabetes, CKD stage 3
Lifestyle changes*
Lifestyle changes  
+ drug treatment starting 
from the 1st visit
Lifestyle changes  
+ drug treatment starting 
from the 1st visit
Overt cardiovascular 
disease, CKD stage ≥ 4
Lifestyle changes*
Lifestyle changes  
+ drug treatment starting 
from the 1st visit
Lifestyle changes  
+ drug treatment starting 
from the 1st visit
Figure 2. Initiation of antihypertensive therapy in relation to blood pressure (BP) values and the global cardiovascular risk 
*In the high normal BP range, antihypertensive drugs are often indicated for reasons other than elevated BP (treatment of  
cardiac events, cardiovascular prevention, nephroprotection) 
ABPM — ambulatory blood pressure measurements; CKD — chronic kidney disease (stage 3: eGFR 30–59 mL/min/1.73 m2; 
stage ≥ 4: eGFR < 30 mL/min/1.73 m2)
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aggressive approach to treatment in the elderly patients with 
grade 1 hypertension, attempts to reduce SBP to the target 
values should not lead to DBP reduction to very low values 
(< 65 mm Hg).
4.1.3. Follow-up visits
Current practice indicates that in the initial treatment phase, 
when the diagnosis of hypertension is confirmed and treat-
ment is initiated and intensified, follow-up visits should be 
set at monthly intervals, and after adequate BP control is 
obtained, their frequency may be reduced to once every 
3 months. Intervals between follow-up visits should also de-
pend on the degree of patient compliance, and the presence 
of target organ damage, concomitant disease, and other risk 
factors. The treatment plan should be adjusted to patient life-
style and needs, with simplification of the therapy, reduction 
of the daily number of tablets taken by the patient, involving 
family members in the treatment process, and tailoring treat-
ment to the financial situation of the patient.
4.2. Non-drug therapy
Non-drug therapy involves lifestyle changes that significantly 
reduce elevated BP, increase effectiveness of drug therapy, 
and probably may reduce the risk of CV events and prevent 
development of hypertension in those with a family history of 
hypertension. However, due to poor patient compliance re-
garding lifestyle changes, their formal recommendation should 
never delay initiation of drug therapy in high risk patients.
Non-drug therapy includes attaining normal body weight, 
appropriate diet with reduction of fat intake, particularly of 
saturated fats, and reduction of alcohol and salt intake, smok-
ing cessation, and increasing regular physical activity.
4.2.1. Weight reduction and  
dietary recommendations
Reduction of excess body weight should be obtained by 
reduction of caloric intake and appropriate diet composition 
(Table 6). Patients are recommended to consume vegetables, 
low-fat dairy products, fibre, and protein from plant sources, 
and to limit their saturated fat and cholesterol intake. Intake 
of fresh fruits is also recommended, although caution should 
be exercised in overweight patients and those with diabetes 
due to high sugar content in fruits. A Mediterranean type 
diet is recommended, as is consumption of fish at least twice 
a week, and fruit and vegetable intake should be 300–400 g 
per day. In hypertensive patients, combining exercise with 
the Dietary Approaches to Stop Hypertension (DASH) study 
diet and weight reduction resulted in more pronounced BP 
and left ventricular mass reduction compared to the DASH 
diet only.
Available data, mostly from observational studies, do not 
indicate a higher risk of incident hypertension or higher BP 
values in persons who regularly consume coffee. In contrast, 
consumption of energy drinks and foods with high fructose 
content should be avoided.
Weight reduction, and particularly reduction of abdomi-
nal obesity, not only results in BP lowering but also reduces 
dyslipidaemia and insulin resistance. It has been estimated that 
reducing body weight by 10 kg contributes to SBP lowering 
by approximately 5–20 mm Hg, and this BP lowering effect is 
more pronounced in obese subjects compared to those with 
near-normal body weight.
4.2.2. Salt intake
A causal relationship has been proven between salt intake and 
BP values. Excessive salt intake may contribute to resistance 
to antihypertensive treatment.
Reduction of sodium intake to 75–100 mmol/day (4.35– 
–5.8 g of salt) results in BP lowering by an average of 
2–8 mm Hg. Hypertensive patients should not consume 
more than 5 g of salt per day (£ 85 mmol of sodium) 
(Table 7). BP-lowering effect of reduction of sodium intake 
is seen in salt-sensitive subjects and is more pronounced in 
blacks, the elderly, and patients with diabetes, metabolic 
syndrome, and CKD. Limiting salt intake allows reduction of 
the number and doses of antihypertensive drugs. Evaluation 
of sodium intake should be based on measurements of 24-h 
urinary sodium excretion, although this approach may be 
prone to a significant error. Despite an inverse relationship 
between sodium excretion and total mortality found in the 
Table 6. Basic dietary recommendations for hypertensive  
patients, aiming for body weight maintenance or reduction  
to normal values
Maintain daily caloric intake or reduce it in case of overweight  
or obesity
Increase intake of vegetables and other plant products  
(4–5 servings) rich in potassium, e.g. tomatoes (300 g/day)*
Avoid products with high animal fat content (saturated fatty  
acids and cholesterol)
Substitute fish, fruits, vegetables, and other products containing 
unsaturated fatty acids for fatty animal products
*Excluding patients with renal failure or increased risk of hyperkalaemia
Table 7. Recommendations regarding salt intake in hyperten-
sive patients
Reduce salt intake from usual 9–12 g to about 5 g per day 
(85 mmol Na). To achieve this target:
 — discontinue using salt when preparing meals at home and at 
the table
 — eat meals prepared from fresh, natural products
 — avoid products containing sodium compounds used as  
preservatives
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general population, no data are available to indicate that 
reducing large or moderate salt intake in hypertensives might 
be harmful. In addition, salt intake reduction in the TOHP 
study was associated with a lower risk of CV events.
4.2.3. Alcohol consumption
A linear relation is observed between alcohol intake and BP 
values. Increased alcohol consumption predisposes to more 
frequent occurrence of strokes and attenuates the effect of 
antihypertensive drugs. If total elimination of alcohol intake 
is not possible, it is recommended:
 — in men: daily alcohol consumption should be reduced 
to 20–30 g of pure ethanol;
 — in women: daily alcohol consumption should be 
reduced to 10–20 g of pure ethanol.
Total weekly alcohol consumption should not exceed 
140 g in men and 80 g in women. The following amounts of 
alcoholic beverages contain 10 g of pure ethanol: 250 mL of 
beer, 100 mL of wine, and 25 g of vodka (Table 8).
4.2.4. Cigarette smoking
Smoking one cigarette induces a significant increase in BP 
and heart rate that persists for more than 15 min. Evidence 
is also available regarding harmful effects of passive smoking. 
In addition, smoking significantly increases the global risk of 
IHD, stroke, and peripheral arterial disease, particularly in 
hypertensive patients. Reducing smoking habit is an impor-
tant component of CV risk reduction efforts in hypertensives 
(Table 9). Smoking status of the patient should be ascertained at 
each visit. Smokers should be counselled to quit. Medications 
to help quit smoking should be considered, including nicotine 
replacement therapy, buproprion, varenicline, and cytisine.
4.2.5. Physical activity
Appropriate physical activity is an important component of 
non-drug therapy. It has been shown that regular exercise 
may reduce BP by 4–9 mm Hg. An increase in physical ac-
tivity also helps reduce overweight, increase general fitness, 
and reduce mortality. Patients with hypertension should be 
advised to engage in at least 30 min of moderate dynamic 
aerobic exercise, such as jogging, brisk walking, cycling, or 
swimming, on 5–7 days per week. Isometric exercises (to build 
up muscle strength without a dynamic component) are not 
recommended. Basic recommendations regarding increasing 
physical activity are summarised in Table 10.
4.3. Antihypertensive medications
The choice of antihypertensive medication(s) should take 
into account the effect of the drug(s) on other CV risk factors, 
the presence of subclinical target organ damage, CVD, and 
other concomitant disease, patient age and gender, possibil-
ity of drug interactions and adverse effects, medication cost 
and financial situation of the patient, and previous physician 
experience with a given therapy. Although the benefits of 
antihypertensive drug therapy in reducing mortality and the 
risk of CV events are largely dependent on BP lowering per se, 
some antihypertensive drug classes are categorised as major, 
and other drug classes do not have this status. The criterion 
underlying this distinction is the presence or absence of data 
from large clinical trials showing significant benefits of a given 
class in reducing mortality and the risk of CV events in patients 
with hypertension. In addition, the position taken in the 
previous PTNT guidelines was upheld that the results of large 
hypertension trials and their metaanalyses published in the 
recent years, including after 2011, along with pathophysiologi-
cal clues and pharmacologic differences, suggest a possibility 
Table 8. Recommendations regarding alcohol intake in  
hypertensive patients
Increased alcohol intake predisposes to increased stroke rates and 
attenuates the effect of antihypertensive drugs
Alcohol intake should be limited to:
 — 20–30 g of pure ethanol daily in men
 — 10–20 g of pure ethanol daily in women
Note: 10 g of pure ethanol corresponds to 250 mL of beer, 100 mL 
of wine, and 25 g of vodka
Table 9. Recommendations regarding smoking in hypertensive 
patients
Each patient should be asked about smoking at each visit
Active counselling should be undertaken regarding smoking cessation
Minimum anti-nicotine intervention should be performed at least 
once a year
If necessary, recommend:
 — nicotine replacement therapy
 — treatment with bupropione
 — treatment with cytosine
 — treatment with varenicline
If these measures fail, refer patients to addiction treatment centres
Weight gain should be prevented
Table 10. Basic recommendations regarding increased physical 
activity in hypertensive patients
Daily systematic exercise of moderate intensity for 30–45 min
Endurance exercises (walking, running, swimming) supplemented 
with resistance exercises (e.g., squatting), adjusted to age,  
concomitant conditions, and patient preferences
Avoidance of isometric exercises (lifting heavy weights)
In patients with cardiac disease, exercise electrocardiogram testing 
and medically supervised rehabilitation may be necessary
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of no class effect and/or better clinical utility of specific drugs 
within their classes, both major ones and others, in specific 
clinical situations, as indicated below when discussing drug 
classes, special patient populations, and individualisation of 
antihypertensive drug therapy.
4.3.1. Major drug classes
In uncomplicated hypertension, and in most cases of com-
plicated hypertension and hypertension with concomitant 
diseases, except for hypertension in pregnancy, antihyper-
tensive therapy should be started with medications from 
the five major drug classes with a proven beneficial effect 
on reducing CV mortality and/or the risk of CV events. These 
are thiazide/thiazide-like diuretics, beta-blockers, calcium 
antagonists, angiotensin-converting enzyme inhibitors 
(ACEI), and angiotensin II (AT1) receptor blockers or sar-
tans (ARB, angiotensin receptor blockers). In accordance 
with the above mentioned position regarding within-class 
differences between drugs, we continue to prefer certain 
subgroups within some major antihypertensive drug classes 
(Table 11).
4.3.1.1. Thiazide/thiazide-like diuretics
Thiazide/thiazide-like diuretics are among first-line drugs 
used as monotherapy, particularly in the elderly patients, 
subjects above 80 years of age (indapamide), and patients 
with a history of stroke. They are also often used as a part of 
two-drug combinations, particularly in patients with concomi-
tant diabetes, those with renal dysfunction or with coexisting 
symptomatic HF, and are a necessary component of three-drug 
combinations in the treatment of more severe hypertension. 
Of note, full BP-lowering effect of thiazide/thiazide-like 
diuretics is seen only after several days of treatment. In the 
recent years, some data have been published indicating that 
thiazide-like diuretics (chlorthalidone, indapamide) should be 
preferred due to more evidence of benefit regarding CV risk 
prevention in large-scale clinical trials (ALLHAT, ADVANCE, 
HYVET, PATS), low utility of hydrochlorothiazide monotherapy 
in currently used low doses of 12.5–25 mg (smaller and 
shorter-lasting BP-lowering effect), and a more beneficial 
metabolic profile of thiazide-like diuretics, although the most 
recent metaanalysis did not confirm the latter difference. The 
two thiazide-like diuretics mentioned above provide a choice 
based on the expected diuretic effect, ranging from moder-
ate (indapamide) to large (chlorthalidone). Attention should 
be paid to possible metabolic (dyslipidaemia and the risk of 
new-onset diabetes) and electrolyte disturbances (hypoka-
laemia, hyperuricaemia, and hyponatremia), and respective 
laboratory parameters should be monitored during long-term 
therapy with conventional thiazide and thiazide-like diuret-
ics due to the fact that an association was observed between 
long-term benefits of these drugs and the occurrence of the 
above mentioned disturbances during treatment. 
Potassium supplementation is often necessary during 
treatment with thiazide/thiazide-like diuretics.
4.3.1.2. Beta-adrenergic receptor blockers
Use of beta-blockers in the treatment of hypertension is 
recommended in patients with tachycardia and/or arrhyth-
mia, evidence of a hyperkinetic circulation, particularly in 
younger subjects, and with concomitant HF or coronary 
artery disease, particularly after a previous MI. Following 
oral administration, BP-lowering effect of beta-blockers is 
seen within several hours but the full treatment effect is 
evident only after several weeks. In the recent years, mul-
tiple controversies arose regarding use of beta-blockers, in 
particular of older generations, as monotherapy in patients 
with hypertension, and thus whether beta-blockers should 
remain among the first-line drugs for the treatment of hyper-
tension. In several large-scale clinical trials in hypertensives, 
conventional cardioselective beta-blockers (atenolol) were 
less effective in preventing CV events compared to inhibi-
tors of the renin–angiotensin–aldosterone system (RAAS) and 
calcium antagonists. Metaanalyses of clinical trials showed 
a lower efficacy of these drugs in inducing regression of left 
ventricular hypertrophy and preventing stroke, which may 
be related to their weaker effect on central aortic pressure. 
However, other metaanalyses showed benefits of conven-
tional cardioselective beta-blockers in the treatment of 
hypertension in patients after an acute coronary syndrome, 
and mortality benefits in hypertensive patients with chronic 
obstructive pulmonary disease (COPD) and heart disease.
The position taken in the previous PTNT guidelines 
was upheld that vasodilating agents (carvedilol, nebivolol) 
should be preferred among beta-blockers in patients with 
uncomplicated hypertension. This has been reflected in 
the text of the 2013 ESH/ESC guidelines that noted some 
beneficial aspects of the mechanism of action of vasodilat-
ing beta-blockers. Due to their haemodynamic properties 
(smaller negative chronotropic effect and a reduction of total 
peripheral resistance), resulting in a more favourable effect 
on central aortic pressure, these drugs should be preferred 
in uncomplicated hypertension if a beta-blocker is indicated. 
Table 11. Major classes of antihypertensive drugs
Five major classes of antihypertensive drugs
With proven outcome benefits
Used as monotherapy
Recommended for combination treatment
Thiazide diuretics (preferred thiazide-like agents)
Beta-blockers (preferred vasodilatatory agents)




Andrzej Tykarski et al.
686
However, appropriate clinical studies would be required to 
document the efficacy of vasodilating beta-blockers in the 
prevention of CV events in hypertensive patients. Additional 
receptor-mediated effects (alpha1-adrenergic receptor block-
ade by carvedilol, beta3-adrenergic receptor activation by 
nebivolol), beneficial effects on metabolic parameters and 
endothelial function, and the results of large-scale clinical tri-
als (GEMINI, COMET, SENIORS) all suggest that vasodilating 
beta-blockers should be preferred if a beta-blocker is indi-
cated in hypertensives with diabetes or metabolic syndrome, 
and in those after CV events and with coexisting CVD. If it 
is necessary to achieve desired heart rate reduction (due 
to coexisting HF, IHD, or aortic dissection), conventional, 
highly cardioselective beta-blockers (bisoprolol, betaxolol, 
metoprolol succinate) may be more useful.
4.3.1.3. Calcium antagonists
An important advantage of calcium antagonists is their neutral 
metabolic effect, and thus these drugs are useful in combina-
tion with RAAS inhibitors in patients with concomitant lipid 
and/or carbohydrate metabolism disturbances. Dihydropyri-
dines should be preferred as monotherapy, as much more 
evidence from large-scale clinical trials (ALLHAT, ASCOT, 
VALUE, ACCOMPLISH) is available for this subgroup. Of 
note, efficacy and safety of long-acting dihydropyridines were 
shown in the elderly, including patients with ISH (Syst-Eur), 
patients with peripheral arterial disease, and those with con-
comitant COPD or asthma. Some metaanalyses suggest high 
efficacy of calcium antagonists in the prevention of athero-
sclerosis, and clinically in the prevention of stroke, but this 
was not confirmed in secondary stroke prevention studies. On 
the other hand, metaanalyses also indicate that these drugs 
are less effective in preventing HF and reducing proteinuria. 
Although most evidence for CV risk reduction in large-scale 
clinical trials was obtained for amlodipine, use of this drug is 
associated with a relatively high rate of leg oedema and thus 
lercanidipine and lacidipine are alternative long-acting but 
better tolerated drugs of this class.
4.3.1.4. Angiotensin-converting enzyme inhibitors  
and angiotensin receptor blockers
Both these classes of RAAS inhibitors are among the most 
commonly used in the treatment of hypertension and have 
most indications in special patient populations. 
ACEI are preferred in hypertension with target organ 
damage or high CV risk, particularly with coexisting IHD, HF 
or renal disease, in hypertension with metabolic syndrome 
and/or diabetes, and, in combination with a thiazide-like 
diuretic, in patients with a history of stroke. Metaanalyses 
suggest additional benefits of ACEI in the prevention of car-
diac events beyond BP lowering effect that may be associated 
with bradykinin-mediated effects of these drugs, particularly 
those with high tissue affinity, such as perindopril (EUROPA 
study). In the SMILE-4 study, sulfhydryl (-SH) group-containing 
zofenopril was more effective compared to ramipril in patients 
with post-infarction left ventricular dysfunction, particularly 
those with hypertension.
ARB are preferred in patients with hypertension and 
left ventricular hypertrophy, concomitant renal disease (in-
cluding diabetic nephropathy), and in those with a history 
of stroke, while in hypertensives with IHD or HF they are 
recommended as an alternative to ACEI if the latter are not 
tolerated. Some metaanalyses suggested that ARB prevent 
stroke better than MI.
The 2013 ESH/ESC guidelines questioned the clinical 
importance of previous suggestions regarding differences 
between ACEI and ARB in regard to CV event prevention, 
based on a large 2009 metaanalysis and the ONTARGET study 
which directly compared the effect of ramipril and telmisartan 
on CV mortality and morbidity in high CV risk patients and 
showed no difference between these two drugs. However, 
three important metaanalyses were published in 2012–2014, 
focusing on different patient populations, i.e. hypertensives, 
patients with hypertension and/or IHD, and diabetic patients, 
that all showed an advantage of ACEI over ARB. The first of 
these metaanalyses suggested a special position of perindopril 
among ACEI, particularly during combination therapy. Taking 
into account consistent results of these metaanalyses, it seems 
reasonable to conclude that ACEI should be preferred over 
ARB (with indications retained for telmisartan) in patients with 
hypertension and high CV risk, i.e., with concomitant CV and 
metabolic complications, a position which has been reflected 
in the table that summarises individualisation of antihyperten-
sive drug therapy. In contrast, ACEI and ARB have equivalent 
positions in uncomplicated hypertension with lower CV risk.
4.3.2. Other antihypertensive drugs
Due to lack of prospective studies evaluating the effect on 
mortality and CV risk, other drug classes, such as alpha-block-
ers, aldosterone antagonists, loop diuretics, imidazoline 
receptor agonists, and peripheral and central sympatholytic 
drugs, are not recommended as first- and second-line anti-
hypertensive medications. However, this does not preclude 
use of these drugs during combination therapy if indicated 
individually, and in resistant hypertension, usually as fourth- 
and fifth-line drugs.
Similarly to major antihypertensive drug classes, patho-
physiological data, pharmacokinetic differences, and varying 
severity of adverse effects suggest better clinical utility of 
specific drugs also within other groups of antihypertensive 
medications (Table 12). This is particularly the case for the pref-
erence of torasemide over furosemide among loop diuretics 
(due to more favourable pharmacokinetics), and eplerenone 
over spironolactone (less adverse effects) among aldosterone 
antagonists, although eplerenone is not licensed to treat 
uncomplicated hypertension in Poland. In patients with 
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concomitant benign prostatic hyperplasia, uroselective tam-
sulosin should be rather used if hypertension requires one- or 
two-drug therapy, while resistant hypertension would require 
doxazosin as this alpha-blocker exerts a BP-lowering effect.
4.4. Drug treatment algorithm
Antihypertensive drug therapy is initiated using one (mono-
therapy) or two (combined therapy) drugs chosen from major 
drug classes. Figure 3 shows the algorithm for the management 
of hypertension, and in particular the decision to initiate treat-
ment with monotherapy or combined therapy depending on 
the severity of hypertension and the degree of BP lowering 
necessary to reach target BP. As target BP values have been 
unified, the algorithm continues not to include CV risk related 
to concomitant metabolic disturbances or CV and renal com-
plications as a criterion for the choice between monotherapy 
and combined therapy.
4.4.1. Monotherapy
In monotherapy, most currently used antihypertensive medica-
tions lower BP by less than 20/10 mm Hg and such an effect 
is observed in only about 50–60% of patients. Thus, therapy 
is initiated with one drug only in grade 1 hypertension. 
It should be remembered that treatment benefits are mostly 
related to BP lowering, and thus medications characterised by 
a high trough-to-peak (T/P) ratio are preferred, particularly dur-
ing monotherapy, as they provide better 24-h BP control and 
may be given once daily which improves patient compliance.
Patient’s age may serve as a pathophysiological clue 
regarding the initial drug choice in uncomplicated hyperten-
sion. RAAS inhibitors and beta-blockers may be effective in 
younger patients, in whom so called resistance or high-renin 
hypertension is often present, and thiazide/thiazide-like diu-
retics and calcium antagonists in older patients, who are more 
frequently characterised by volume or low-renin hypertension. 
Patient gender may also be factor, as RAAS inhibitors should 
be avoided in women of reproductive years, and beta-blockers 
or calcium antagonist should be preferred instead.
Increasing the drug dose to the maximum dose exerts little 
additional BP lowering effect but largely increases the risk of 
adverse effects. Thus, if monotherapy using a standard drug 
dose does not produce the desired effect, adding a second 
drug has been considered the optimal next step among pos-
sible options.
4.4.2. Combined therapy
Most patients with hypertension require two-drug therapy 
for appropriate BP control. This is the case in half of patients 
with grade 1 hypertension and in most patients with higher 
baseline BP values. Thus, therapy is initiated with two drugs 
in grade 2 and 3 hypertension, with an option of increasing 
the dose of one or both drugs to the maximum dose.
Major two-drug combinations used in the treatment of 
hypertension, which are well tolerated, effectively lower BP, 
and reduce CV risk, include:
 — ACEI + calcium antagonist;
 — ACEI + thiazide/thiazide-like diuretic;
Figure 3. Management algorithm for antihypertensive drug therapy; BP — blood pressure





Central sympatholytic agents (clonidine)
Imidazoline receptor antagonists (rilmenidine)
Peripheral sympatholytic agents (methyldopa)
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 — ARB + thiazide/thiazide-like diuretic;
 — ARB + calcium antagonist;
 — ACEI + beta-blocker;
 — calcium antagonist + beta-blocker;
 — calcium antagonist + thiazide/thiazide-like diuretic.
Inclusion of the last two combinations among the pre-
ferred two-drug combinations in the current guidelines is 
related to the fact of their practical use in two important 
patient groups: the elderly (calcium antagonist + thiazide/ 
/thiazide-like diuretic), which was also reflected in the 
2013 ESH/ESC guidelines, and young/middle-aged women 
(beta-blocker + dihydropyridine calcium antagonist) in 
whom RAAS inhibitors should be avoided.
In patients with hypertension and cardiac disease (IHD, 
HF), the preferred combination of ACEI and beta-blocker is 
commonly used. It is the only preferred two-drug combina-
tion without available fixed-dose combination drug products.
In the current guidelines, the combination of beta-blocker 
and thiazide diuretic has been considered acceptable due to 
multiple trials that documented its benefits vs. placebo in the 
early era of evidence-based medicine, as also reflected in the 
2013 ESH/ESC guidelines. It should be remembered, however, 
that such combinations are generally less effective in reducing 
CV risk (ASCOT and LIFE studies) and may be associated with 
a higher risk of metabolic disturbances and new-onset diabe-
tes, although this risk is mitigated if the combination involves 
a thiazide-like diuretic and/or a vasodilating beta-blocker.
Note: RAAS inhibitors should be very cautiously com-
bined with potassium-sparing diuretics as this may lead to 
hyperkalaemia. The combination of ACEI and ARB is not 
recommended due to an increased risk of adverse renal ef-
fects without additional benefits, as confirmed in the recent 
metaanalyses. Non-dihydropyridine calcium antagonists 
(verapamil and diltiazem) combined with beta-blockers 
predispose to bradycardia and HF, and diuretics combined 
with alpha-blockers predispose to orthostatic hypotension. 
The preferred two-drug combinations in the treatment of 
hypertension are summarised in Figure 4.
About 30% of patients require at least three drugs for 
adequate BP control. In uncomplicated hypertension, the 
basic three-drug combination includes a RAAS inhibitor, 
a calcium antagonist, and a thiazide/thiazide-like diuretic.
When selecting antihypertensive drugs for combination 
therapy, the major criterion should be an increase of their 
therapeutic effect with improved treatment tolerance.
4.4.3. Fixed-dose combinations  
of antihypertensive drugs
Combined therapy benefits from the use of fixed-dose combi-
nations of antihypertensive drugs, as this increases treatment 
effectiveness (STITCH and ACCOMPLISH studies), simplifies 
the treatment scheme, and increases patient compliance 
(metaanalyses). In addition, the use of fixed-dose combinations 
is associated with an increased antihypertensive efficacy com-
pared to the algorithm of monotherapy-combined treatment, 
while use of lower doses minimises the risk of dose-related 
adverse effects. Fixed-dose combinations are recommended 
to initiate antihypertensive drug therapy in patients with grade 
2 hypertension, as reflected in the management algorithm. 
Among the seven listed preferred two-drug combinations, 
six are available in Poland as fixed-dose combination drug 
products. Our decision to supplement the basic combinations 
of a RAAS inhibitor with a calcium antagonist or a thiazide/thi-
azide-like diuretic with two others (thiazide/thiazide-like diu-
retic + calcium antagonist and beta-blocker + dihydropyridine 
calcium antagonist) was related, among other factors, to the 
introduction of such fixed-dose combinations in Poland (inda-
pamide + amlodipine and bisoprolol + amlodipine).
An interesting addition to the armamentarium of fixed-dose 
combination drug products in Poland has been the introduc-
tion of three-drug fixed-dose combinations, offering the 
possibility of single tablet therapy also in patients with higher 
baseline BP values, including those with grade 3 hyperten-
sion. Both available three-drug fixed-dose combinations 
(ACEI + dihydropyridine calcium antagonist + thiazide-like 
diuretic and ARB + dihydropyridine calcium antagonist + thi-
azide-like diuretic) fulfil the criteria of an optimal drug com-
bination in uncomplicated hypertension. Of note, analyses 
of randomised studies indicate potential benefits in terms of 
CV risk reduction for the available three-drug combination 
of perindopril + indapamide + amlodipine.
In the future, combined therapy using doses lower than 
standard ones available in two-and three-drug fixed-dose 
combinations may prove to be an alternative approach to 
Figure 4. Two-drug combinations of antihypertensive drugs; 
ACEI — angiotensin-converting enzyme inhibitor; ARB —  
angiotensin receptor blocker
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initiating antihypertensive therapy in patients with grade 1 and 
grade 2/3 hypertension, respectively.
4.4.4. Chronotherapy of hypertension
Studies based on ABPM indicate that in many patients, ad-
ditional CV risk is associated with masked nocturnal hyperten-
sion, non-dipping BP pattern, or excessive morning BP surge. 
Typical morning dosing of long-acting antihypertensive drugs 
may not correct these disturbances of the circadian BP profile. 
In these circumstances, particularly with the non-dipping BP 
pattern or masked nocturnal hypertension, modification of 
the timing of antihypertensive drug administration should 
be considered, with evening drug dosing (Fig. 5). As this ap-
proach to chronotherapy of hypertension, first suggested in 
the 2011 PTNT guidelines, has become popular in Poland, it 
should be noted that evening dosing of antihypertensive drugs 
must be based on evaluation by ABPM (non-dipping pattern) 
and rather involve dosing of RAAS inhibitors. Evening dosing of 
ARB or ACEI (with a preference given rather to shorter-acting 
drugs and those tested in chronotherapy studies, e.g. ramipril 
and valsartan) was associated with an improved circadian 
BP pattern, reduced microalbuminuria, and proved safe in 
large-scale clinical trials (HOPE, Syst-Eur). Unless nocturnal 
hypertension is found, evening dosing of antihypertensive 
drugs is contraindicated in patients with glaucoma.
5. SPECIAL PATIENT POPULATIONS
The approach to drug therapy adopted in the current and 
previous guidelines gives much emphasis to its individualisa-
tion (Tables 13, 14).
The choice of first-line therapy is important due to potential 
benefits beyond BP lowering documented in large-scale clinical 
trials for specific types of CV and renal events and metabolic 
disturbances in hypertension, or a possibility to obtain addi-
tional benefits or avoid adverse effects in case of concomitant 
diseases. Due to widespread use of combination therapy, rec-
ommendations regarding individualisation of antihypertensive 
drug therapy also extend to second-line drugs in specific clinical 
scenarios. Specific indications for and contraindications to dif-
ferent drug classes are shown in Tables 14 and 15, and indica-
tions for the use of different drug combinations or fixed-dose 
combination drug products are shown in Figure 6.
5.1. Hypertension in the elderly
Large clinical trials and metaanalyses indicate that antihyper-
tensive therapy in patients above 65 years of age significantly 
reduces the rate of strokes, HF incidence, and CV mortality. 
Patients with SBP ≥ 160 mm Hg were recruited to these stud-
ies, and SBP was lowered below 150 mm Hg but not below 
140 mm Hg. Thus, antihypertensive therapy may be clearly 
recommended in the elderly patients with grade 2 hyperten-
sion, in whom SBP should be lowered to 140–150 mm Hg. 
However, due to rational reasons and the fact that persons 
above 65 years of age constituted a significant proportion of 
patients in many clinical trials, antihypertensive therapy should 
also be considered in those with SBP above 140 mm Hg, 
aiming for target SBP below 140 mm Hg, if the patient is in 
a good overall condition and tolerates the therapy well. In 
patients above 80 years of age, based on the results of the 
HYVET study, it may be generally recommended to initiate an-
tihypertensive therapy if SBP is above 160 mm Hg, aiming for 
target SBP below 150 mm Hg. However, due to differences in 
the general health condition of these individuals, the decision 
to initiate therapy should be individualised, and BP lowering 
should be gradual and carefully monitored by the physician. 
In the elderly patients with concomitant disease, such as 
coronary artery disease, CKD or diabetes, specific target BP 
values accepted for these clinical conditions should apply.
Benefits of antihypertensive therapy in the elderly are 
comparable to those obtained in younger age groups. How-
ever, due to a reduced adaptive capacity of the CV system and 
the risk of orthostatic hypotension, therapy should be more 
cautious, and target BP values should be reached more gradu-
ally. Due to the risk of orthostatic hypotension and falls, BP in 
the elderly hypertensive should be measured after 1 and 3 min 
of standing (orthostatic testing) in the following situations:
Table 13. Individualisation of drug therapy
When choosing (or avoiding) any particular drug (or drug  
combination), the following should be taken into consideration:
Presence of cardiovascular and renal disease
Presence of other concomitant conditions
Presence of other cardiovascular risk factors and target organ damage
Demographic factors (age, gender, race, body weight)
24-h blood pressure-lowering efficacy of a drug
Drug adverse effect profile
Drug cost — but never at the price of lower treatment effectiveness 
and tolerance
Previous physician and patient experience with a given drug (drugs)
Figure 5. Suggested timing of antihypertensive drug admini-
stration in relation to the 24-h blood pressure (BP) profile
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otherwise, first-line drugs are thiazide/thiazide-like diuretics 
and dihydropyridine calcium antagonists or their combina-
tion. In clinical trials in patients with the most common type 
of hypertension in the elderly, ISH, only diuretics and calcium 
antagonists with a possible addition of a RAAS inhibitor were 
used. In patients above 80 years of age, available studies 
(HYVET) indicate that the therapy should be initiated with 
a long-acting thiazide-like diuretic (indapamid), with a pos-
sible addition of an ACEI (Table 16).
5.2. Hypertension in women
In the Blood Pressure Lowering Treatment Trialists’ Collabora-
tion metaanalysis that compared benefits of antihypertensive 
therapy in men and women, both similar BP-lowering effect 
and similar treatment outcomes were noted in both genders, 
Table 14. Preferred first (I) and second (II) choice antihypertensive drug classes in specific conditions
Clinical condition Preferred first and second choice drugs
DT BB CA-dhp CA-ndhp ACEI ARB AA LD MD
Left ventricular hypertrophy I I
Ischaemic heart disease I II A II B I 1 II C 2 II D
Heart failure II I 3 I II C 4 II II
Permanent atrial fibrillation I I
Tachyarrhythmias I
Aortic dissection I
Peripheral arterial disease I I
Previous stroke I 5 II I
Metabolic syndrome II II I I
Diabetes II 5 II I I
High-risk patients (multiple cardiovascular  
and metabolic complications)
I 6 II C 7
Gout II I I B
Hypertension in the elderly I I II II
Hypertension above 80 years of age I 9 II
Isolated systolic hypertension I I II II
Albuminuria/proteinuria II II I I
Diabetic/non-diabetic nephropathy I I
Chronic kidney disease I I II 
Pregnancy II 10 II 11 II 12 I
Erectile dysfunction II 13 II I I
Asthma/chronic obstructive pulmonary disease I I
Glaucoma I
I — first choice drug; II — second choice drug 
A — with angina; B — with beta-blocker intolerance; C — with ACEI intolerance; D — after myocardial infarction 
1 — preferred agents: perindopril, ramipril, zofenopril; 2 — preferred agents: telmisartan and valsartan; 3 — only carvedilol, bisoprolol, meto-
prolol XR/CR, nebivolol; 4 — preferred agents: candesartan and valsartan; 5 — preferred agent: indapamide; 6 — preferred agents: perindopril, 
ramipril; 7 — telmisartan has the first-choice status; 8 — preferred agent: losartan; 9 — only indapamide; 10 — preferred agent: labetalol (poor 
availability in Poland), of other beta-blockers only metoprolol; 11 — only nifedipine (extended release preparation preferred); 12 — only verapamil;  
13 — only nebivolol 
DT — thiazide/thiazide-like diuretics; BB — beta-blockers; CA-dhp — dihydropyridine calcium antagonists; CA-ndhp — non-dihydropyridine  
calcium antagonists; ACEI — angiotensin-converting enzyme inhibitors; ARB — angiotensin receptor blockers; AA — aldosterone antagonists;  
LD — loop diuretics; MD — methyldopa
 — therapy initiation;
 — treatment change;
 — history of falls;
 — dizziness or near-fainting;
 — concomitant diabetes.
Although the basic principles of non-drug therapy in the 
elderly hypertensives are the same as in younger subjects, 
limitations due to impaired mobility and reduced fitness, 
precluding regular exercise, should be borne in mind.
All major classes of antihypertensive medications were 
tested in large-scale clinical trials in the elderly patients, and 
recent metaanalyses do not indicate any differences in the 
efficacy of antihypertensive medications in relation to the 
patient’s age. However, as dictated by the clinical experience, 
and if there are no specific indications to individualise therapy 
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Table 15. Absolute and relative contraindications to specific antihypertensive drug classes
Drug class Absolute contraindications Relative contraindications
Diuretics Gout (thiazides) Metabolic syndrome
Glucose intolerance
Hyponatremia < 130 mmol/L
Pregnancy
Beta-blockers Asthma
Grade 2 or 3 AVB 
Chronic obstructive pulmonary disease
Metabolic syndrome
Glucose intolerance
Athletes and physically active patients
Dihydropyridine calcium antagonists Tachyarrhythmias
Heart failure
Non-dihydropyridine calcium antagonists 
(verapamil/diltiazem)
Grade 2 or 3 AVB 
Heart failure
Bradycardia < 50 bpm
Chronic constipation (verapamil)
Angiotensin-converting enzyme inhibitors Pregnancy
Hyperkalaemia > 5.0 mmol/L
Bilateral or single kidney renal artery stenosis
Transplant renal artery stenosis
History of angioneurotic oedema
Angiotensin receptor blockers Pregnancy
Hyperkalaemia > 5.0 mmol/L
Bilateral or single kidney renal artery stenosis
Aldosterone antagonists Transplant renal artery stenosis
Chronic kidney disease (eGFR < 30 mL/min)
Hyperkalaemia > 5.0 mmol/L
Pregnancy
AVB — atrioventricular block; eGFR — estimated glomerular filtration rate
with no differences in response to different class of antihyper-
tensive medications. In women who plan pregnancy or are 
potentially able to conceive, use of ACEI and ARB should be 
avoided due to potential teratogenic effects of these drugs.
Hypertension is not an absolute contraindication for the 
use of hormonal replacement therapy or oral contraception. 
If these therapies are used, BP should be measured at each 
visit and hypertension should be treated according to the 
general management principles.
The likelihood of BP increase in hypertensive women who 
receive hormonal replacement therapy during menopause 
is small, but hormonal replacement therapy and selective 
oestrogen receptor modulators should not be use for primary 
or secondary prevention of CV events.
Use of oral contraceptives is associated with a small but 
significant BP increase and development of hypertension. 
However, most studies evaluated the effect of older genera-
tion contraceptives that contained a higher oestrogen dose 
than those currently used. Data are lacking regarding the ef-
fect of newer hormonal contraceptive methods (vaginal and 
transdermal) on BP but an association was confirmed between 
newer contraceptive methods and an increased risk of venous 
thrombosis. Progestin-only containing oral contraceptives 
(minipills) are not considered contraindicated in mild and 
moderate hypertension but they constitute a minor proportion 
of currently used oral contraceptives. 
5.3. Hypertension in pregnant women
There are two major types of hypertension in pregnancy:
 — chronic (preexisting) hypertension — BP ≥ 140/ 
/90 mm  Hg before pregnancy or developing before 
20 weeks of gestation and persisting beyond 12 weeks 
after delivery;
 — gestational (pregnancy-induced) hypertension — de-
veloping after 20 weeks of gestation and resolving within 
12 weeks after delivery.
Preeclampsia is a multiorgan dysfunction syndrome com-
plicating hypertension in pregnancy, with a serious prognosis 
for the pregnancy itself and future CV risk of the woman. It 
usually develops between 20 weeks of gestation and 3 days 
after delivery, with worse pregnancy outcomes if it occurs 
early, particularly before 32 weeks of gestation. It is defined as:
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 — gestational (pregnancy-induced hypertension) — new-
onset BP ≥ 140/90 mm Hg (mean of ≥ 2 measurements 
within ≥ 4 h, and if BP ≥ 160/110 mm Hg — within 
minutes); and
 — any of the following findings occurring de novo: pro-
teinuria (≥ 300 mg/24 h, protein/creatinine ratio ≥ 0.3, 
protein 1+ or more on reagent strip), low platelet count 
(< 100,000/µL), renal function worsening (serum creati-
nine > 1.1 mg/dL or doubling of the serum creatinine 
level in CKD), hepatic dysfunction (increase in alanine 
transaminase/aspartate transaminase level to two times 
the upper limit of normal), pulmonary oedema, central 
nervous system signs or symptoms, vision disturbances.
Preeclampsia is likely related to placental dysfunction 
and thus develops mostly in the second half of pregnancy 
in pregnancy-induced hypertension but may also occur in 
Figure 6. Preferred choices of combined therapy/fixed-dose combination products and intensification of antihypertensive drug 
therapy in relation to concomitant conditions; ACEI — angiotensin-converting enzyme inhibitor; BP — blood pressure; MI —  
myocardial infarction; RAAS — renin–angiotensin–aldosterone system
Table 16. Antihypertensive treatment strategies in the elderly
Drug therapy to reduce SBP to between 150 and 140 mm Hg is recommended in patients aged 65–80 years with grade 2–3 hypertension
In patients > 80 years with grade 2–3 hypertension, drug therapy to reduce SBP to between 150 and 140 mm Hg is recommended, provided 
the patient is in a good physical and mental condition
In patients aged 65–80 years with grade 1 hypertension, drug therapy with a target SBP < 140 mm Hg may be considered if the treatment is 
well tolerated
In patients who reach 80 years of age, continuation of previous antihypertensive therapy may be considered regardless of on-treatment blood 
pressure values
In patients > 80 years with grade 1 hypertension, drug therapy is not recommended
In the elderly, initial drug doses should be lower, and subsequent therapy intensification should be more cautious due to a higher risk of 
adverse effects (hypotension)
Due to a reduced intellectual capacity of the elderly, treatment should be simplified, with frequent use of fixed-dose combination drug products
All major drug classes may be used, with some preference of thiazide/thiazide-like diuretics and dihydropyridine calcium antagonists, and 
therapy intensification using a RAAS inhibitor
In the elderly with isolated systolic hypertension, thiazide/thiazide-like diuretics and dihydropyridine calcium antagonists are preferred
In patients > 80 years, the preferred first line drug is indapamide, and the second line drug is ACEI
ACEI — angiotensin-converting enzyme inhibitor; RAAS — renin–angiotensin–aldosterone system; SBP — systolic blood pressure
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women with preexisting hypertension, in whom BP elevation 
with other features of preeclampsia is seen after 20 weeks of 
gestation — this is diagnosed as preeclampsia superimposed 
upon chronic hypertension.
If hypertension was first found after 20 weeks of gesta-
tion, without other evidence of preeclampsia, and previous 
BP values are unknown or uncertain, antenatally unclassified 
hypertension should be diagnosed and the diagnosis should 
be verified at or beyond 12 weeks after delivery.
Other serious complications of hypertension in pregnancy 
include the HELLP syndrome (clotting abnormalities, hepatic 
dysfunction, and low platelet count) and eclampsia, or symp-
toms of central nervous system dysfunction.
Is secondary hypertension (renal artery stenosis or phaeo-
chromocytoma) is suspected in a pregnant woman, appropri-
ate investigations and treatment should be undertaken before 
the third trimester, and the optimal approach would to be to 
perform full diagnostic work-up for secondary hypertension 
before pregnancy.
The principles of antihypertensive treatment in pregnant 
women are summarised in Table 17.
5.4. Hypertension in patients with  
metabolic syndrome
Hypertension or high normal BP is a frequent component of 
metabolic syndrome. Recommending lifestyle changes, par-
ticularly body weight reduction and increased physical activity, 
is very important in all individuals with metabolic syndrome 
as the first and foremost intervention in the management of 
hypertension. The aim is to reduce body weight by 7–10% 
over 6–12 months by modest reduction of caloric intake (by 
500–1000 kcal per day) which is usually more effective than 
a more rigorous diet.
Antihypertensive drug therapy is recommended for 
BP ≥ 140/90 mm Hg, with the aim to lower BP below 
140/90 mm Hg. Currently, no evidence from outcome trials 
justifies initiation of drug treatment in patients with metabolic 
syndrome and high normal BP. Metabolic syndrome is associated 
with a high risk of developing diabetes, and thus the effect of 
antihypertensive drugs on glucose metabolism should be taken 
into consideration when choosing between drug classes. Drug 
therapy should be initiated with RAAS inhibitors which delay de-
velopment of diabetes, with the addition of a calcium antagonist 
if necessary. Beta-blockers and conventional thiazide diuretics 
should be avoided in patients with metabolic syndrome. If drugs 
from these classes are indicated, vasodilating beta-blockers and 
thiazide-like diuretics should be chosen. When prescribing a diu-
retic, a potassium-sparing preparation should be considered, as 
hypokalaemia worsens glucose tolerance.
5.5. Hypertension in diabetic patients
The prevalence of hypertension among diabetic patients is 
increased compared to the general population. Nighttime 
hypertension is common and often masked. Thus, ABPM is 
recommended in each diabetic patient.
BP should also be measured in the standing position in 
case of symptoms suggesting hypotension during therapy in-
tensification.
In patients with hypertension and diabetes, antihyperten-
sive drug therapy is typically recommended when BP is above 
Table 17. Antihypertensive treatment strategies in pregnant women
In all pregnant women, modified non-drug treatment is recommended (no alcohol intake and smoking, limitation of physical activity),  
without limitation of salt intake
Drug treatment is recommended if BP is ≥ 150/95 mm Hg in pregnant women with uncomplicated and asymptomatic preexisting  
hypertension, and ≥ 140/90 mm Hg in women with pregnancy-induced hypertension (regardless of the presence of proteinuria),  
and complicated, symptomatic, or secondary preexisting hypertension
Target BP in pregnant women is < 140/90 mm Hg. Frequent evaluation by ABPM is recommended
BP values ≥ 170/110 mm Hg should be considered an indication for hospital admission
In pregnant women with hypertension, the preferred drug is methyldopa. Labetalol* may be added in the first trimester, and metoprolol 
tartrate and/or calcium antagonist (nitrendipine or nifedipine SR* or verapamil) may be added starting from the second trimester
Hydralazine* may be considered as a fourth-line drug. Continuation of pre-pregnancy treatment with a thiazide diuretic is controversial 
(harmful effects of hypovolaemia in preeclampsia and an increased risk of schizophrenia in children)
In severe hypertension that cannot be controlled by oral drugs, nitroglycerin by intravenous infusion, intravenous labetalol, or intravenous 
urapidil may be used. Seizure prevention is also necessary using intravenous magnesium sulphate that also has a BP-lowering effect
The following drugs are absolutely contraindicated during pregnancy and breastfeeding due to observed or potential teratogenic effects: 
ACEI, ARB, renin inhibitors, aldosterone antagonists, and diltiazem
All antihypertensive drugs are secreted to breast milk, and thus the same drugs are recommended during lactation as during pregnancy
Hypertension is an indication for acetylsalicylic acid 75–150 mg daily starting from 12 weeks of gestation until delivery to prevent preeclampsia
*Drugs not routinely available in Poland, may be imported individually by a physician prescription 
ABPM — ambulatory blood pressure monitoring; ACEI — angiotensin-converting enzyme inhibitors; ARB — angiotensin receptor blockers; BP — 
blood pressure
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140/90 mm Hg. No evidence is available from outcome clini-
cal trials that would justify initiating drug therapy in patients 
with diabetes and high normal BP. Recent analyses indicate 
that optimal reduction of the global CV risk in most patients 
with hypertension and diabetes is obtained by lowering BP 
below 140/85 mm Hg. The change of the target DBP value 
has been based on an analysis of HOT and UKPDS study 
findings. Benefits of BP lowering below 130/80 mm Hg in 
diabetic patients have not been confirmed in the ACCORD 
and INVEST studies and are debatable also in patients with 
concomitant diabetic nephropathy.
Effective BP control in diabetic patients is difficult and 
thus these patients more often require combined antihyper-
tensive drug therapy. Due to a proven nephroprotective ef-
fect of RAAS inhibitors, ACEI or ARB should be an invariable 
component of combination therapy and the preferred choice 
in monotherapy. When choosing between ACEI and ARB in 
diabetic patients, results of the most recent metaanalysis of 
studies performed in this group of patients may be taken into 
consideration, showing a greater long-term cardioprotective 
effect of ACEI. For combined therapy, first choices should 
include an ACEI with a calcium antagonist (ACCOMPLISH) 
or a thiazide-like diuretic (ADVANCE). Recently reported 
results of the ADVANCE ON study showed for the first time 
that antihypertensive therapy with a fixed-dose combination 
(perindopril + indapamide) may yield long-term (10 years) 
outcome benefits.
Concomitant administration of two RAAS inhibitors 
(also including the renin inhibitor) should be avoided due to 
a higher risk of hyperkalaemia and worsening of renal function 
(ONTARGET and ALTITUDE studies).
The management of patients with hypertension and 
diabetes should be particularly targeted at improvement of 
all CV risk factors. This means a strong indication for a statin, 
and the need to consider possible benefits of acetylsalicylic 
acid (ASA) (Table 18).
5.6. Hypertension in patients with  
chronic kidney disease
Observational studies show a direct correlation between 
BP values and development of CKD. Protection from fur-
ther progression of renal disease requires strict BP control 
(<  140/90 mm Hg) and reducing proteinuria as much as 
possible. Lowering BP below 130/80 mm Hg to delay albu-
minuria is questionable (ROADMAP study), and in patients 
with hypertension and concomitant nephropathy with large 
proteinuria it remains a domain of nephrologists.
Compared to other classes of antihypertensive medica-
tions, ACEI and ARB are more effective at reducing proteinu-
ria and delaying progression of renal disease, and thus are 
indicated in patients with moderately reduced glomerular 
filtration rate (GFR) and/or proteinuria. Therapy should be 
started with low doses that are later cautiously increased to 
moderate ones, with monitoring of creatinine and potassium 
levels. Reduction of baseline estimated GFR (eGFR) by 30% 
during the first 4–12 weeks of therapy should be considered 
acceptable. ACEI and ARB should not be used in patients with 
acute kidney injury, and initiation of these drugs is not recom-
mended, unless supervised by a nephrologist, in patients with 
CKD and eGFR below 30 ml/min/1.73 m2.
Combined therapy using several antihypertensive drugs is 
usually required to reach target BP. Based on the results of the 
ACCOMPLISH study, it was shown that a combination of an 
ACEI with a calcium antagonist rather than a thiazide diuretic 
is more effective at preventing doubling of serum creatinine 
level and development of end-stage renal disease. The type 
and dose of a diuretic should be adjusted to renal function. 
Thiazide and thiazide-like diuretics should not be used in 
patients with eGFR below 30 mL/min, and loop diuretics 
should be used instead. Doses of loop diuretics should be 
increased with worsening of renal function.
In advanced CKD, mineralocorticoid receptor antagonists 
are not recommended, particularly in combination with 
ACEI/ARB, due to a risk of renal function worsening and 
development of hyperkalaemia. If mineralocorticoid receptor 
antagonists are used in this patient group, strict monitoring of 
potassium level is required. Combining two RAAS inhibitors is 
also not recommended despite potentially higher effectiveness 
in reducing proteinuria. The latter two therapeutic options 
should remain a domain of nephrologists.
5.7. Hypertension complicated by  
ischaemic heart disease
Hypertension is an important factor in the pathogenesis of 
IHD (accelerated atherosclerosis, left ventricular hypertrophy). 
Table 18. Antihypertensive treatment strategies in patients 
with diabetes
Antihypertensive drug therapy is recommended in patients with 
grade 1–3 hypertension
Target BP in patients with diabetes is < 140/85 mm Hg
The presence of proteinuria does not modify target BP
In diabetes, RAAS inhibitors (ACEI and ARB) are recommended due 
to a greater nephroprotective effect
Combined drug treatment is more often required to obtain good 
BP control
Thiazide diuretics (thiazide-like agents are preferred) and dihydro-
pyridine calcium antagonists are recommended in combination 
with a RAAS inhibitor
It is not recommended to combine two RAAS inhibitors
Statin therapy is recommended
Acetylsalicylic acid may be considered
ACEI — angiotensin-converting enzyme inhibitors; ARB — angiotensin 
receptor blockers; BP — blood pressure; RAAS — renin–angiotensin– 
–aldosterone system
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In patients with hypertension in whom BP is lowered below 
140/90 mm Hg, a clear reduction of the CV event rate is seen 
compared to patients with on-treatment BP values above 
140/90 mm Hg, regardless of the drug classes used.
Long-term data from the INVEST study showed that in 
both patients with strict BP control (SBP < 130 mm Hg) and 
those with uncontrolled BP (SBP > 140 mm Hg), outcomes 
were worse than in patients with SBP 130–140 mm Hg, 
confirming the existence of the J curve in this patient group.
Although optimal BP reduction is the most important 
factor, recommended antihypertensive drugs in patients with 
concomitant IHD are ACEI (preferred drugs of this class are 
perindopril — EUROPA study, ramipril — HOPE study, and 
zofenopril — SMILE 4 study) and beta-blockers, particularly 
in patients after a MI. If angina is present, calcium antago-
nists are also used. In patients with concomitant IHD, ARB 
are second-choice drugs (preferred ones are telmisartan — 
ONTARGET study, and in patients after a MI also valsartan 
— VALIANT study) in case of ACEI intolerance, based on 
the results of multiple metaanalyses comparing these two 
drug classes in regard to reduction of the risk of death and 
cardiac events.
5.8. Hypertension complicated by heart failure
Along with IHD, hypertension is one of the two major causes 
of HF. It often leads to left ventricular diastolic dysfunction 
and HF with preserved ejection fraction. It is also the most 
important modifiable risk factor for the development of HF, 
and thus preventing HF involves use of antihypertensive 
drugs. Diuretics, beta-blockers, ACEI, and ARB were shown 
to be beneficial in the prevention of HF, while calcium an-
tagonists are less effective in this regard.
In advanced HF, hypertension becomes less problematic 
due to reduction of cardiac output in this condition, and higher 
BP values are prognostically favourable. Any antihypertensive 
therapy should be undertaken with consideration of the current 
guidelines on the management of HF, which means that the 
preferred drugs in this patient group are beta-blockers (only 
carvedilol, bisoprolol, metoprolol XR/CR, and nebivolol), ACEI 
(drugs studied in postinfarction left ventricular dysfunction 
include lisinopril, ramipril, trandolapril, and zofenopril), and 
aldosterone antagonists (eplerenone is the preferred drug). ARB 
are second-choice drugs in case of ACEI intolerance (preferred 
drugs of this class are candesartan and valsartan).
Diuretics are recommended in patients with clinical 
evidence of left- or right-sided HF. The preferred drugs are 
thiazide-like diuretics with greater natriuretic effect (chlo-
rthalidone) and loop diuretics, which induce an even stronger 
natriuretic effect. Among the latter, torasemide is characterised 
by greater bioavailability, better absorption, and longer half-life 
compared to furosemide, and exerts an additional anti-aldos-
terone effect, which translated to increased clinical benefits 
observed in the non-randomised TORIC study (Table 19).
5.9. Hypertension complicated by atrial fibrillation
Hypertension is the most common condition coexisting with 
atrial fibrillation (AF), and it is considered a reversible cause of 
this arrhythmia. In patients with AF with rapid ventricular rate, 
beta-blockers and non-dihydropyridine calcium antagonists 
are recommended. In patients with hypertension who are at 
risk of de novo AF, ACEI or ARB should be considered, al-
though studies that evaluated reduction of the risk of recurrent 
AF during treatment with these drugs yielded contradictory 
results. In hypertension complicated by IHD, the risk of AF re-
currence is probably reduced by any effective antihypertensive 
drug, and if HF is present, the risk is reduced by eplerenone.
Each patient with hypertension and permanent or recur-
rent AF requires anticoagulation, preferably using oral anticoag-
ulants other than vitamin K antagonists (dabigatran, rivaroxaban, 
apixaban), to prevent stroke. In patients using anticoagulants, 
good BP control is particularly important to reduce the rate of 
bleeding events associated with anticoagulant therapy.
5.10. Hypertension and prevention of stroke
Regardless of the type of therapy, effective BP lowering 
reduces stroke risk more effectively than the risk of IHD. 
Metaanalyses indicate, however, that beta-blockers are 
less effective and calcium antagonists are more effective 
at reducing stroke risk compared to other antihypertensive 
drug classes.
Table 19. Antihypertensive treatment strategies in patients 
with heart disease
Target BP in patients with heart disease is < 140/90 mm Hg, and 
the likelihood of a clinical J-curve effect is particularly high in this 
patient group
Preferred antihypertensive drugs in patients with ischaemic heart 
disease, and particularly after a myocardial infarction, are ACEI and 
beta-blockers, and in patients with angina also calcium antagonists
Preferred antihypertensive drugs in patients with heart failure are 
ACEI and beta-blockers, followed by aldosterone antagonists, and 
diuretics in symptomatic patients
In patients with ischaemic heart disease and/or heart failure, ARB 
are alternative second choice drugs in case of ACEI intolerance
In patients with AF with rapid ventricular response, beta-blockers 
and possibly non-dihydropyridine calcium antagonists are recom-
mended as antihypertensive drugs
Every hypertensive patient with heart disease requires statin and 
acetylsalicylic acid
Every hypertensive patient with AF requires antithrombotic  
treatment, preferentially with a novel oral anticoagulant
In patients with a risk of de novo or recurrent AF, ACEI or ARB may 
be considered for antihypertensive drug therapy, and eplerenone 
may be considered in patients with concomitant heart failure
ACEI — angiotensin-converting enzyme inhibitors; AF — atrial fibrilla-
tion; ARB — angiotensin receptor blockers; BP — blood pressure
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Long-term after stroke or a transient ischaemic attack, 
the goal of therapy should be normalisation of BP (target 
BP < 140/90 mm Hg should be reached slowly, and provided 
that treatment is well tolerated). The reported data indicate 
efficacy of thiazide-like diuretics (indapamide in the PATS 
study and combined with perindopril in the PROGRESS study) 
and ARB (eprosartan in the MOSES study) in the secondary 
prevention of stroke. In contrast, the effect of antihypertensive 
drug therapy on the severity of vascular dementia has not been 
documented. During each visit, BP should be measured in 
the standing position to avoid excessive BP falls.
Due attention should also be paid to other basic elements 
of secondary stroke prevention, such as lifestyle modification 
and treating risk factors, anticoagulation, use of antiplatelet 
agents, and surgical treatment of carotid artery stenosis.
In the acute phase of stroke, hypertension should only be 
treated if SBP exceeds 220 mm Hg or DBP exceeds 120 mm 
Hg, and the drug if choice in these circumstances is labetalol 
(or, if it is unavailable, intravenous agents with medium du-
ration of action). BP should be slowly reduced to values not 
lower than 180/110 mm Hg.
In the SCAST study, no significant effect of antihyperten-
sive drug therapy in the acute phase of stroke was found on 
CV events, including recurrent stroke.
Fibrinolytic therapy may be used if BP is lower than 
185/110 mm Hg. On the second day after stroke, antihyper-
tensive therapy may be initiated if BP is higher than 180 and/or 
120 mm Hg (Table 20).
5.11. Other concomitant conditions
5.11.1. Hypertension with sexual dysfunction
Erectile dysfunction is more common in hypertensives than 
in individuals with normal BP values. Sexual dysfunction is 
considered an independent CV risk factor and a possible 
marker of atherosclerosis.
Multiple studies showed that antihypertensive drug therapy 
using older generation diuretics and beta-blockers increases 
the risk of erectile dysfunction in men. Compared to these 
drugs, newer antihypertensive drug classes, i.e. ARB and ACEI, 
have a neutral or even beneficial effect on erectile function. In 
contrast to conventional beta-blockers, nebivolol exerts a va-
sodilatatory effect related to nitric oxide release. Several studies 
showed that nebivolol may have a more beneficial effect on 
erectile dysfunction in men compared to other beta-blockers.
5.11.2. Hypertension and chronic lung disease
No studies compared the effect of antihypertensive therapy 
using different drug classes on long-term outcomes in patients 
with concomitant COPD.
However, knowledge of pharmacologic properties and 
adverse drug effect registries indicates that calcium antago-
nists and ARB may be considered safe antihypertensive drugs 
in patients with COPD. Caution is required when using 
ACEI (cough inducing bronchospasm) and beta-blockers 
(bronchospasm). If a drug from the latter class is required, 
its choice must be carefully dictated by cardioselectivity or 
additional protective properties, and attention must be paid 
to the recommended dose to minimise the effect on lung 
ventilation parameters. Cardioselective beta-blockers were 
found to reduce mortality among patients with COPD and 
concomitant cardiac disease.
5.11.3. Hypertension and glaucoma
The safest antihypertensive drugs that are not associated with 
a risk of glaucoma incidence and progression are beta-blockers.
Among the risk factors for glaucoma, in addition to high 
BP, an increasing attention has been paid to systemic hypoten-
sion which may lead to reduced perfusion of the optic disc and 
induce glaucoma lesions. It seems that systemic hypotension 
is a much more important risk factor for progression of visual 
field defects than hypertension. Thus, overly aggressive anti-
hypertensive therapy may lead to progression of glaucoma. 
Most importantly, adverse effects of antihypertensive therapy 
include excessive nocturnal BP fall with secondary reduction 
of ocular perfusion. In patients with glaucoma, evening dos-
ing of antihypertensive drugs is contraindicated unless ABPM 
shows very high BP values during the night.
5.11.4. Hypertension and gout
The preferred choice for antihypertensive therapy in patients 
with concomitant gout is losartan, as this drug reduces hyperu-
ricaemia, which might be of importance for the reduction of 
CV risk (LIFE study), but there are no contraindications for 
other ARB, ACEI, and calcium antagonists in patients with hy-
peruricaemia. In contrast, drugs that increase serum acid level, 
Table 20. Antihypertensive treatment strategies in stroke 
patients
Target BP in patients after a stroke or TIA is < 140/90 mm Hg. 
BP should be reduced slowly, with target values reached about 
2 weeks after the acute event, provided that the treatment is well 
tolerated
Antihypertensive drug therapy for the secondary prevention of 
stroke should be based on a thiazide-like diuretic with a possible 
addition of an ACEI, or based on an ARB
In the elderly patients after a stroke or TIA, somewhat higher target 
BP may be considered
Other major components of secondary prevention are indicated, 
such as lifestyle changes and treatment of risk factors, anticoagu-
lant and antiplatelet treatment, and surgical treatment of carotid 
artery disease (if indicated)
In the acute phase of stroke, treatment of hypertension is indicated 
only for BP > 220/120 mm Hg
ACEI — angiotensin-converting enzyme inhibitor; ARB — angiotensin 
receptor blockers; BP — blood pressure; TIA — transient ischaemic 
attack
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mostly thiazide/thiazide-like diuretics and beta-blockers, are 
not recommended. Allopurinol, which is used for long-term 
therapy of gout, may also be considered in hypertensives 
with asymptomatic hyperuricaemia, particularly those with 
CVD, due to a proven beneficial effect of this drug on the 
improvement of endothelial function and aortic compliance.
5.11.5. Hypertension and benign  
prostatic hyperplasia
When treating hypertension in men with benign prostatic 
hyperplasia, the general principles of antihypertensive therapy 
in the elderly using major drug classes should apply, and 
the previous recommendation to initiate therapy with an 
alpha-blocker has been abandoned after the ALLHAT study. 
The decision to use an alpha1-adrenergic receptor antagonist 
to improve micturition should be made by an urologist, with 
consideration of uroselective drugs (e.g., tamsulosin) for bet-
ter cardiac safety in patients on established antihypertensive 
therapy. Non-selective alpha1-blockers (e.g., doxazosin) are 
among useful third- and fourth-line antihypertensive drugs, 
particularly in resistant hypertension (ASCOT study).
5.11.6. Hypertension and psoriasis
The prevalence of hypertension in patients with psoriasis is 
increased compared to the general population, as is resistance 
to treatment. The pathogenesis of hypertension in patients 
with psoriasis is related, among other factors, to systemic 
inflammation. Beta-blockers should be avoided in hyperten-
sives with psoriasis and no concomitant IHD, as these drugs 
may worsen psoriasis.
5.11.7. Hypertension in the perioperative period
Preoperatively, it is not desirable to aim for full BP normalisa-
tion by intensifying previous therapy. Target BP values may be 
in the range of 140–160/90–100 mm Hg (due to an additional 
BP-lowering effect of anaesthetics).
Previous antihypertensive drug therapy may be generally 
continued, with usual morning dose of BP-lowering drugs. If 
possible, withholding diuretics 2–3 days before a major surgery 
should be considered (due to potential adverse effects related 
to fluid loss and hypokalaemia), and maybe also RAAS inhibi-
tors on the day of the surgery (with the last dose taken on the 
day before the surgery). In the recent years, controversies have 
arisen around the use of beta-blockers in the perioperative 
period. Potential benefits of these drugs are limited to patients 
with a history of MI or with HF, and thus patient populations 
in which long-term use of beta-blockers is indicated anyway. 
In other patients, initiating beta-blocker therapy, particularly 
several days before the surgery, may be associated with an 
increased mortality risk. In the recent ESC guidelines, more 
consideration has been given to perioperative statin than 
beta-blocker use.
5.12. Resistant hypertension
Resistant hypertension is defined as BP values ≥ 140/90 mm Hg 
during appropriate combination therapy with three drugs (in-
cluding a diuretic) in adequate doses.
Using this definition, resistant hypertension is a common 
clinical problem. In Poland, the proportion of patients with 
resistant hypertension has been estimated at 10–13% of all 
treated hypertensives. Patients with resistant hypertension 
are characterised by an increased CV risk compared to those 
with good on-treatment BP control. Cardiovascular risk is also 
related to the number of antihypertensive drugs used.
Most commonly, pseudoresistance to treatment is ob-
served due to the following reasons:
 — non-compliance;
 — inappropriate drug treatment — too low drug doses, drug 
combinations including no diuretic;
 — BP increase in office measurements (white coat effect);
 — errors during BP measurement;
 — pseudohypertension.
The most common identifiable and correctable reasons 
for treatment resistance include:
 — lack of appropriate lifestyle modifications, including body 
weight increase and consumption of large amounts of 
alcohol;
 — taking medications and substances that raise BP (e.g., 
non-steroidal anti-inflammatory drugs, glucocorticoster-
oids, cocaine, licorice etc.);
 — undiagnosed secondary hypertension; common causes 
include obstructive sleep apnoea, renal disease, primary 
hyperaldosteronism, and renal artery stenosis;
 — volume overload due to inappropriate diuretic treatment, 
progressive renal dysfunction, and large sodium intake;
 — advanced, irreversible vascular damage leading to 
a significant increase in the arteriolar wall-to-lumen ratio 
or reduced large artery compliance.
After excluding these often difficult-to-eliminate causes, 
the prevalence of true resistant hypertension is much lower. 
In patients with true resistant hypertension, SBP values are 
usually very high, and the prevalence of severe left ventricular 
hypertrophy and renal dysfunction is increased.
5.12.1. Drug therapy of resistant hypertension
The algorithm for the management of resistant hypertension 
is shown in Table 21 and Figure 7.
The recommended and effective three-drug combi-
nation includes a RAAS inhibitor, thiazide/thiazide-like 
diuretic, and a calcium antagonist. In some patients with 
resistant hypertension, changing previous medications to 
this three-drug combination, also using fixed-dose combined 
preparations, may be associated with an improvement of 
BP control. In resistant hypertension, a good response has 
been seen to a mineralocorticoid receptor antagonist as the 
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next treatment step, particularly spironolactone, even in 
low doses (25–50 mg/day). An alpha-blocker (doxazosin) or 
beta-blocker may also be considered. In regard to the choice 
of a beta-blocker, benefits of vasodilating beta-blockers 
(carvedilol, nebivolol) have been highlighted. As the next 
step, it may be worth using a loop diuretic, particularly 
torasemide, instead of a thiazide/thiazide-like diuretic, in 
particular in patients with renal dysfunction, and obligatorily 
in patients with eGFR below 30 mL/min/1.73 m2. Of note, 
some older generation antihypertensive drugs may be ef-
fective in the treatment of resistant hypertension, i.e. direct 
arterial vasodilators (hydralazine) and central sympatholytic 
drugs (clonidine, rilmenidine).
In resistant hypertension, twice daily dosing of antihy-
pertensive drugs is frequently necessary.
5.12.2. Renal denervation
Renal denervation is based on a solid theoretical background 
to expect effectiveness of this approach in the treatment 
of hypertension. Initial results of the Symplicity-HTN1 and 
Table 21. Antihypertensive treatment strategies in patients with resistant hypertension
Pseudoresistance should be excluded and correctable causes of treatment resistance should be eliminated before institution of additional therapy
In patients who are unsuccessfully treated with a RAAS inhibitor, diuretic, and calcium antagonist in maximal doses, an aldosterone antago-
nist should be added
The next step should be addition of an alpha-blocker (doxazosin) or a beta-blocker (vasodilatatory agents are preferred)
The next step should be substitution of a loop diuretic for thiazide/thiazide-like diuretic, particularly in patients with severe kidney dysfunction
As the next step, addition of a direct arteriolar vasodilator (hydralazine) or a central acting agent (clonidine) should be considered
In exceptional cases of truly resistant hypertension, after all the above drug treatment measures have been tried, invasive treatment  
(renal denervation) may be considered
Patient selection for renal denervation should be a domain of hypertension specialists, and these procedures should be performed by invasive 
cardiologists in specialised centres
RAAS — renin–angiotensin–aldosterone system
Figure 7. Management algorithm in resistant hypertension; ABPM — ambulatory blood pressure measurements; BP — blood pressure
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HTN2 studies indicated that this procedure is highly effec-
tive. In addition, a beneficial effect on the glycaemic profile 
and improvement of the apnoea–hypopnea index in patients 
with obstructive sleep apnoea was seen. The interest in renal 
denervation and its importance as the last-resort therapy of 
resistant hypertension decreased significantly with the publica-
tion of the results of the randomised Symplicity-HTN3 study, 
showing no significant BP-lowering effect at 6 months of 
follow-up. Although further analyses showed higher efficacy 
of renal denervation in Caucasians, patients below 65 years 
of age, those without renal failure and treated with an aldos-
terone antagonist, even in these patient groups the overall 
BP reduction was modest, below 10 mm Hg. However, the 
procedure was shown to be safe. In contrast, the randomised 
PRAGUE-15 study showed that renal denervation is equally 
effective at lowering BP as adding spironolactone, and the 
randomised DENERHTN study showed that in patients with 
resistant hypertension despite use of a RAAS inhibitor, a cal-
cium antagonist and a diuretic, denervation was associated 
with more effective BP lowering than adding further antihy-
pertensive medications, including spironolactone.
According to the current expert opinion on renal dener-
vation in the treatment of hypertension in Poland, published 
before the results of Symplicity-HTN3, PRAGUE-15 and 
DENERHTN studies were reported, this procedure is indi-
cated for office SBP ≥ 160 mm Hg (mean of three measure-
ments) during treatment with at least three antihypertensive 
medications in full doses, including a diuretic. Secondary 
Clinical profile Blood pressure [mm Hg]
High normal  
(130–139/85–89)
Grade 1 hypertension 
(140–159/90–99)
Grade 2 hypertension 
(160–179/100–109)





LDL < 115 mg/dL
Statin
LDL < 115 mg/dL
Statin
LDL < 100 mg/dL
≥ 3 risk factors 
Statin
LDL < 115 mg/dL
Statin
LDL < 100 mg/dL
Statin
LDL < 100 mg/dL
Target organ damage, 
diabetes, CKD stage 3
Statin
LDL < 100 mg/dL
Statin
LDL < 100 mg/dL
Statin
LDL < 100 mg/dL
Statin
LDL < 100 mg/dL
Overt cardiovascular 
disease, CKD stage ≥ 4
Statin
LDL < 70 mg/dL
Statin
LDL < 70 mg/dL
Statin
LDL < 70 mg/dL
Statin
LDL < 70 mg/dL
Figure 8. Indications for statin therapy in hypertensive patients in relation to the global cardiovascular risk 
CKD — chronic kidney disease (stage 3: eGFR 30–59 mL/min/1.73 m2; stage ≥ 4: eGFR < 30 mL/min/1.73 m2); LDL — low density 
lipoprotein
Clinical profile Blood pressure [mm Hg]
High normal  
(130–139/85–89)
Grade 1 hypertension 
(140–159/90–99)
Grade 2 hypertension 
(160–179/100–109)
Grade 3 hypertension 
(≥ 180/110)
No risk factors ASA
(after BP is normalized!)
1–2 risk factors ASA
(after BP is normalised!)
≥ 3 risk factors ASA
(after BP is normalised!)
ASA
(after BP is normalised!)
Target organ damage, 
diabetes, CKD stage 3
ASA
ASA
(after BP is normalised!)
ASA
(after BP is normalised!)
ASA
(after BP is normalised!)
Overt cardiovascular 
disease, CKD stage ≥ 4
ASA ASA ASA ASA
Figure 9. Indications for the treatment with acetylsalicylic acid (ASA) in hypertensive patients in relation to the global cardiova-
scular risk  
BP — blood pressure; CKD — chronic kidney disease (stage 3: eGFR 30–59 mL/min/1.73 m2; stage ≥ 4: eGFR < 30 mL/min/1.73 m2)
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hypertension, and in particular primary hyperaldosteronism, 
should be excluded in these patients. Following release of the 
Symplicity-HTN3 study, it seems reasonable to add spirono-
lactone to drug treatment in patients who are considered 
candidates for renal denervation.
Currently, pending confirmation of the long-term effec-
tiveness of renal denervation, it is recommended that patient 
selection for this procedure should be limited to specialised 
hypertension units, and these procedures should be per-
formed by experienced invasive cardiologists.
6. TREATMENT OF CONCOMITANT RISK  
FACTORS (NON-BP-LOWERING THERAPY)
6.1. Lipid-lowering drugs
Hypercholesterolaemia is more prevalent in hypertensive 
patients compared to the general population, as is atherogenic 
dyslipidaemia in patients with concomitant diabetes. Multiple 
clinical trials on the use of statins in primary and secondary 
prevention, in which hypertensive patients constituted a sig-
nificant proportion of the study populations, indicate that an 
optimal reduction of the global CV risk may be obtained by 
simultaneous reduction of BP and low density lipoprotein 
cholesterol (LDL-C) level. In patients with hypertension and 
CVD, statin treatment is mandatory based on the general 
guidelines of cardiac societies that recommend serum LDL-C 
level lowering below 70 mg/dL. Based on the results of recent 
randomised clinical trials, systematic reviews, and metaanaly-
ses, optional LDL-C level lowering below 55 mg/dL has been 
even suggested in patients at the highest CV risk.
Initiation of statin treatment is also recommended in 
all high and very high risk patients (10-year risk of a CV 
event > 20%) without overt CVD regardless of the degree 
of BP elevation (atorvastatin in the ASCOT study), aiming 
for target serum LDL-C level below 100 mg/dL, and accord-
ing to some societies below 70 mg/dL. In the ASCOT study, 
it was also shown that adding a statin to amlodipine- and 
perindopril-based antihypertensive treatment reduced the 
CV event rate more than adding a statin to atenolol- and 
thiazide diuretic-based treatment. Statin should also be used 
in hypertensive patients with moderate CV risk (> 15–20%; 
rosuvastatin in the JUPITER study), even in case of moderate 
hypercholesterolaemia, aiming for target serum LDL-C level 
below 115 mg/dL (Fig. 8).
6.2. Antiplatelet therapy
In patients with hypertension and CVD, use of ASA is man-
datory based on the general guidelines of cardiac societies 
that recommend a 75 mg dose. In these cases, ASA treat-
ment should be used regardless of the degree of BP control. 
A useful fixed-dose combination product in these patients is 
a combination of beta-blocker and ASA (bisoprolol + ASA).
A recently published large metaanalysis that evaluated the 
rates of major bleeding events in patients receiving long-term 
ASA treatment has changed the approach to the use of this 
drug in primary prevention. It has been shown that the net 
benefits of ASA, measured as the difference between the CV 
event rate reduction and the increase in the major bleeding 
event rate, have not been clearly established in this patient 
population. Thus, use of ASA for this indication requires 
evaluation of the risk-to-benefit ratio. Based on these recent 
reports, a low ASA dose should be considered only in hyper-
tensive patients with a high (20–30%) or very high (> 30%) 
global CV risk. To minimise the risk of haemorrhagic stroke, 
it is recommended to initiate ASA treatment in these patients 
only after elevated BP has been fully controlled (Fig. 9). In 
view of these increasing limitations regarding the use of ASA in 
primary prevention, alternative substances with antiaggregant 
properties that have been evaluated in clinical trials (e.g., 
standardised tomato extract which exerts a weaker antiplatelet 
effect compared to ASA but has a more pleiotropic activity 
range) may be considered in patients with uncomplicated 
hypertension and moderate to high CV risk.
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